SCHEMBL13073441

SCHEMBL13073441

COC(=O)O[C@H]1CN(C(=O)OC(C)(C)C)CCN1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX1 P07099 1/20 0.38
MAPK1 P28482 2/20 0.38
NR1H2 P55055 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.37
EPHX2 P34913 1/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27752719 0.86 USP2 (0.41) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL2561810 0.86 USP2 (0.41) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL28127594 0.85 USP2 (0.42) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL28136162 0.85 USP2 (0.42) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL7768121 0.84 USP2 (0.37) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL27481655 0.82 NR1H2 (0.40) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL19051326 0.79 USP2 (0.40) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL24940 0.78 USP2 (0.41) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL881661 0.78 USP2 (0.41) USP2SMN1; SMN2EPHX1MAPK1NR1H2
SCHEMBL1350453 0.78 USP2 (0.41) USP2SMN1; SMN2EPHX1MAPK1NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834004-B2 Sulfonyl-substituted bicyclic compounds as modulators of PPAR KALYPSYS, INC (US) 2010-11-16 US disclosed
US-20090264417-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR KALYPSYS, INC. (US) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264417-A1 SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR PPARG, PPARA, PPARD USP2 4135/4885SMN1; SMN2 2454/4885EPHX1 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.